Which has higher valuation & earnings, PLSE or BWAY?

Brainsway has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 7,347.93 -$72.78M -$1.10 N/A Brainsway $56.22M 11.18 $7.57M $0.35 44.77

Does the media refer more to PLSE or BWAY?

In the previous week, Pulse Biosciences had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Pulse Biosciences and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat Pulse Biosciences' score of 0.23 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, BWAY or LMAT?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $56.22M 11.18 $7.57M $0.35 44.77 LeMaitre Vascular $249.60M 9.42 $57.73M $2.71 37.99

Does the media refer more to BWAY or LMAT?

In the previous week, LeMaitre Vascular had 3 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for LeMaitre Vascular and 3 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 0.76 beat Brainsway's score of 0.42 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, AXGN or BWAY?

Brainsway has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.80 -$15.70M -$0.68 N/A Brainsway $56.22M 11.18 $7.57M $0.35 44.77

Is AXGN or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.36%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Brainsway 15.68% 12.28% 7.75%

Does the media favor AXGN or BWAY?

In the previous week, AxoGen had 22 more articles in the media than Brainsway. MarketBeat recorded 25 mentions for AxoGen and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat AxoGen's score of 0.42 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 8 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, NVCR or BWAY?

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $699.19M 2.57 -$136.23M -$1.30 N/A Brainsway $56.22M 11.18 $7.57M $0.35 44.77

Is NVCR or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Brainsway 15.68% 12.28% 7.75%

Does the media favor NVCR or BWAY?

In the previous week, NovoCure had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for Brainsway. NovoCure's average media sentiment score of 0.82 beat Brainsway's score of 0.42 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BFLY or BWAY?

In the previous week, Butterfly Network had 28 more articles in the media than Brainsway. MarketBeat recorded 31 mentions for Butterfly Network and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat Butterfly Network's score of 0.34 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 13 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Brainsway 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Brainsway (BWAY) Competitors

$15.67 +0.44 (+2.88%)

As of 10:51 AM Eastern

Compare

BWAY vs. PLSE, LMAT, AXGN, NVCR, and BFLY

Should you buy Brainsway stock or one of its competitors? MarketBeat compares Brainsway with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainsway include Pulse Biosciences (PLSE), LeMaitre Vascular (LMAT), AxoGen (AXGN), NovoCure (NVCR), and Butterfly Network (BFLY).

How does Brainsway compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Brainsway has a net margin of 15.68% compared to Pulse Biosciences' net margin of 0.00%. Brainsway's return on equity of 12.28% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Brainsway	15.68%	12.28%	7.75%

Pulse Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Pulse Biosciences presently has a consensus target price of $32.33, indicating a potential downside of 12.99%. Brainsway has a consensus target price of $15.67, indicating a potential downside of 0.01%. Given Brainsway's stronger consensus rating and higher possible upside, analysts plainly believe Brainsway is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Brainsway has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	7,347.93	-$72.78M	-$1.10	N/A
Brainsway	$56.22M	11.18	$7.57M	$0.35	44.77

In the previous week, Pulse Biosciences had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for Pulse Biosciences and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat Pulse Biosciences' score of 0.23 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Brainsway beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.

How does Brainsway compare to LeMaitre Vascular?

Brainsway (NASDAQ:BWAY) and LeMaitre Vascular (NASDAQ:LMAT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, LeMaitre Vascular had 3 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for LeMaitre Vascular and 3 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 0.76 beat Brainsway's score of 0.42 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Brainsway presently has a consensus target price of $15.67, suggesting a potential downside of 0.01%. LeMaitre Vascular has a consensus target price of $112.60, suggesting a potential upside of 9.38%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$56.22M	11.18	$7.57M	$0.35	44.77
LeMaitre Vascular	$249.60M	9.42	$57.73M	$2.71	37.99

LeMaitre Vascular has a net margin of 24.35% compared to Brainsway's net margin of 15.68%. LeMaitre Vascular's return on equity of 15.36% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
LeMaitre Vascular	24.35%	15.36%	9.78%

Summary

LeMaitre Vascular beats Brainsway on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Brainsway has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.80	-$15.70M	-$0.68	N/A
Brainsway	$56.22M	11.18	$7.57M	$0.35	44.77

AxoGen has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

AxoGen currently has a consensus target price of $51.00, suggesting a potential upside of 12.77%. Brainsway has a consensus target price of $15.67, suggesting a potential downside of 0.01%. Given AxoGen's higher probable upside, equities analysts plainly believe AxoGen is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Brainsway has a net margin of 15.68% compared to AxoGen's net margin of -13.36%. Brainsway's return on equity of 12.28% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Brainsway	15.68%	12.28%	7.75%

In the previous week, AxoGen had 22 more articles in the media than Brainsway. MarketBeat recorded 25 mentions for AxoGen and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat AxoGen's score of 0.42 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Brainsway beats AxoGen on 12 of the 17 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -21.25%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Brainsway	15.68%	12.28%	7.75%

NovoCure presently has a consensus price target of $21.20, suggesting a potential upside of 37.15%. Brainsway has a consensus price target of $15.67, suggesting a potential downside of 0.01%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

84.6% of NovoCure shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Brainsway has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$699.19M	2.57	-$136.23M	-$1.30	N/A
Brainsway	$56.22M	11.18	$7.57M	$0.35	44.77

In the previous week, NovoCure had 1 more articles in the media than Brainsway. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for Brainsway. NovoCure's average media sentiment score of 0.82 beat Brainsway's score of 0.42 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Summary

Brainsway beats NovoCure on 12 of the 17 factors compared between the two stocks.

How does Brainsway compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Brainsway (NASDAQ:BWAY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Brainsway has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$112.14M	18.20	-$77.06M	-$0.29	N/A
Brainsway	$56.22M	11.18	$7.57M	$0.35	44.77

37.8% of Butterfly Network shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Butterfly Network has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

In the previous week, Butterfly Network had 28 more articles in the media than Brainsway. MarketBeat recorded 31 mentions for Butterfly Network and 3 mentions for Brainsway. Brainsway's average media sentiment score of 0.42 beat Butterfly Network's score of 0.34 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	13 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Brainsway has a net margin of 15.68% compared to Butterfly Network's net margin of -66.74%. Brainsway's return on equity of 12.28% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
Brainsway	15.68%	12.28%	7.75%

Butterfly Network currently has a consensus target price of $5.56, suggesting a potential downside of 30.60%. Brainsway has a consensus target price of $15.67, suggesting a potential downside of 0.01%. Given Brainsway's stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Brainsway	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Summary

Brainsway beats Butterfly Network on 11 of the 17 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$627.58M	$5.72B	$6.81B	$12.55B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	44.68	23.62	282.12	24.83
Price / Sales	11.18	57.68	573.08	78.59
Price / Cash	65.05	32.53	28.60	46.71
Price / Book	8.38	6.43	11.02	6.15
Net Income	$7.57M	$151.15M	$3.49B	$347.61M
7 Day Performance	-0.58%	2.70%	0.47%	1.17%
1 Month Performance	3.15%	-1.83%	-4.24%	-3.46%
1 Year Performance	173.22%	4.26%	62.63%	19.43%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	3.6371 of 5 stars	$15.67 +2.9%	$15.67 0.0%	+165.6%	$627.58M	$56.22M	44.68	120	Analyst Upgrade
PLSE Pulse Biosciences	1.3999 of 5 stars	$34.98 +6.7%	$32.33 -7.6%	+138.2%	$2.42B	$350K	N/A	140	Upcoming Earnings Gap Up
LMAT LeMaitre Vascular	3.8781 of 5 stars	$102.51 +3.6%	$112.60 +9.8%	+25.0%	$2.34B	$249.60M	37.74	490	Upcoming Earnings Analyst Downgrade
AXGN AxoGen	2.8408 of 5 stars	$40.78 -0.9%	$46.50 +14.0%	+233.1%	$2.16B	$225.21M	N/A	450	News Coverage Positive News Earnings Report
NVCR NovoCure	3.1849 of 5 stars	$16.63 -2.3%	$21.20 +27.5%	+31.1%	$1.92B	$674.41M	N/A	1,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. PLSE, LMAT, AXGN, NVCR, and BFLY

How does Brainsway compare to Pulse Biosciences?

Summary

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to AxoGen?

Summary

How does Brainsway compare to NovoCure?

Summary

How does Brainsway compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. PLSE, LMAT, AXGN, NVCR, and BFLY

How does Brainsway compare to Pulse Biosciences?

Do insiders and institutionals hold more shares of PLSE or BWAY?

Is PLSE or BWAY more profitable?

Which has more risk and volatility, PLSE or BWAY?

Do analysts prefer PLSE or BWAY?

Which has higher valuation & earnings, PLSE or BWAY?

Does the media refer more to PLSE or BWAY?

Summary

How does Brainsway compare to LeMaitre Vascular?

Does the media refer more to BWAY or LMAT?

Which has more risk & volatility, BWAY or LMAT?

Do institutionals & insiders believe in BWAY or LMAT?

Do analysts recommend BWAY or LMAT?

Which has stronger valuation and earnings, BWAY or LMAT?

Is BWAY or LMAT more profitable?

Summary

How does Brainsway compare to AxoGen?

Which has higher earnings & valuation, AXGN or BWAY?

Which has more volatility and risk, AXGN or BWAY?

Do analysts prefer AXGN or BWAY?

Is AXGN or BWAY more profitable?

Does the media favor AXGN or BWAY?

Do institutionals & insiders hold more shares of AXGN or BWAY?

Summary

How does Brainsway compare to NovoCure?

Is NVCR or BWAY more profitable?

Do analysts recommend NVCR or BWAY?

Do institutionals & insiders hold more shares of NVCR or BWAY?

Which has preferable valuation and earnings, NVCR or BWAY?

Does the media favor NVCR or BWAY?

Which has more risk & volatility, NVCR or BWAY?

Summary

How does Brainsway compare to Butterfly Network?

Which has better earnings and valuation, BFLY or BWAY?

Do institutionals & insiders believe in BFLY or BWAY?

Which has more risk and volatility, BFLY or BWAY?

Does the media favor BFLY or BWAY?

Is BFLY or BWAY more profitable?

Do analysts rate BFLY or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools